Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
Potts, Kyle G, Irwin, Chad R, Favis, Nicole A, Pink, Desmond B, Vincent, Krista M, Lewis, John D, Moore, Ronald B, Hitt, Mary M, Evans, David H
Published in EMBO molecular medicine (01.05.2017)
Published in EMBO molecular medicine (01.05.2017)
Get full text
Journal Article
Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton
Irwin, Chad R, Favis, Nicole A, Agopsowicz, Kate C, Hitt, Mary M, Evans, David H
Published in PloS one (31.12.2013)
Published in PloS one (31.12.2013)
Get full text
Journal Article
Vaccinia-based vaccines to biothreat and emerging viruses
Nagata, Les P., Irwin, Chad R., Hu, Wei-gang, Evans, David H.
Published in Biotechnology & genetic engineering reviews (02.01.2018)
Published in Biotechnology & genetic engineering reviews (02.01.2018)
Get full text
Journal Article
Initial characterization of Vaccinia Virus B4 suggests a role in virus spread
Burles, Kristin, Irwin, Chad R, Burton, Robyn-Lee, Schriewer, Jill, Evans, David H, Buller, R. Mark, Barry, Michele
Published in Virology (New York, N.Y.) (01.05.2014)
Published in Virology (New York, N.Y.) (01.05.2014)
Get full text
Journal Article
In-fusion® cloning with vaccinia virus DNA polymerase
Irwin, Chad R, Farmer, Andrew, Willer, David O, Evans, David H
Published in Methods in molecular biology (Clifton, N.J.) (2012)
Published in Methods in molecular biology (Clifton, N.J.) (2012)
Get more information
Journal Article